Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

Clinical trial NCT07067385 · RECRUITING

Trial details

NCT number: NCT07067385
Sponsor: Ruijin Hospital
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy Gastrointestinal Tumors

Start date: 2025-07-01
Primary completion: 2027-12-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.